{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Opdivo&page=5",
    "query": {
      "intervention": "Opdivo",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 1207,
    "total_pages": 121,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Opdivo&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Opdivo&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T20:27:23.621Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03816332",
      "title": "Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8",
        "Metastatic Basal Cell Carcinoma",
        "Metastatic Melanoma",
        "Metastatic Merkel Cell Carcinoma",
        "Metastatic Skin Squamous Cell Carcinoma",
        "Pathologic Stage III Cutaneous Melanoma AJCC v8",
        "Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8",
        "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8",
        "Unresectable Basal Cell Carcinoma",
        "Unresectable Melanoma",
        "Unresectable Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2019-11-08",
      "completion_date": "2027-09-17",
      "has_results": true,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-19T20:27:23.621Z",
      "location_count": 7,
      "location_summary": "Tampa, Florida • Chicago, Illinois • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03816332"
    },
    {
      "nct_id": "NCT05780736",
      "title": "A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Esophageal Carcinoma",
        "Gastroesophageal Junction Carcinoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2023-08-04",
      "completion_date": "2024-08-23",
      "has_results": false,
      "last_update_posted_date": "2024-09-25",
      "last_synced_at": "2026-10-19T20:27:23.621Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • San Luis Obispo, California • Santa Maria, California + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Luis Obispo",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05780736"
    },
    {
      "nct_id": "NCT04652960",
      "title": "Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8",
        "Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Duvelisib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Punch Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2021-10-21",
      "completion_date": "2026-12-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-19T20:27:23.621Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Aurora, Colorado • Coral Gables, Florida + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04652960"
    },
    {
      "nct_id": "NCT04493203",
      "title": "Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Melanoma",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Axitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yana Najjar",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2020-12-18",
      "completion_date": "2025-04-12",
      "has_results": true,
      "last_update_posted_date": "2025-07-15",
      "last_synced_at": "2026-10-19T20:27:23.621Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04493203"
    },
    {
      "nct_id": "NCT02631746",
      "title": "Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Adult T-Cell Leukemia/Lymphoma",
        "Adult T-Cell Leukemia/Lymphoma",
        "Chronic Adult T-Cell Leukemia/Lymphoma",
        "HTLV-1 Infection",
        "Lymphomatous Adult T-Cell Leukemia/Lymphoma",
        "Smoldering Adult T-Cell Leukemia/Lymphoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacogenomic Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2017-02-23",
      "completion_date": "2019-07-31",
      "has_results": true,
      "last_update_posted_date": "2025-03-14",
      "last_synced_at": "2026-10-19T20:27:23.621Z",
      "location_count": 6,
      "location_summary": "Baltimore, Maryland • Bethesda, Maryland • The Bronx, New York + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02631746"
    },
    {
      "nct_id": "NCT03519308",
      "title": "A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Paricalcitol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2020-07-29",
      "completion_date": "2022-04-18",
      "has_results": true,
      "last_update_posted_date": "2024-03-15",
      "last_synced_at": "2026-10-19T20:27:23.621Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03519308"
    },
    {
      "nct_id": "NCT04458909",
      "title": "Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Nasopharyngeal Carcinoma",
        "Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma",
        "Metastatic Nasopharyngeal Nonkeratinizing Carcinoma",
        "Metastatic Nasopharyngeal Undifferentiated Carcinoma",
        "Nasopharyngeal Nonkeratinizing Carcinoma",
        "Recurrent Nasopharyngeal Carcinoma",
        "Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma",
        "Recurrent Nasopharyngeal Undifferentiated Carcinoma",
        "Stage IV Nasopharyngeal Carcinoma AJCC v8",
        "Stage IVA Nasopharyngeal Carcinoma AJCC v8",
        "Stage IVB Nasopharyngeal Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2020-12-09",
      "completion_date": "2023-08-15",
      "has_results": true,
      "last_update_posted_date": "2025-10-03",
      "last_synced_at": "2026-10-19T20:27:23.621Z",
      "location_count": 322,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 204 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04458909"
    },
    {
      "nct_id": "NCT04200963",
      "title": "A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Urothelial Carcinoma Bladder",
        "Bladder Cancer",
        "Bladder Disease",
        "Solid Tumor",
        "Solid Carcinoma",
        "Solid Tumor, Adult",
        "Metastatic Cancer",
        "Advanced Solid Tumor",
        "Advanced Cancer",
        "Metastatic Bladder Cancer",
        "Metastatic Urothelial Carcinoma",
        "Locally Advanced Solid Tumor",
        "Neoplasms",
        "Neoplasm Metastasis",
        "Neoplasm Malignant",
        "Neoplasm, Bladder",
        "Urothelial Neoplasm",
        "Neoplasm, Urinary Bladder",
        "Bladder Neoplasm",
        "Bladder Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "IK-175",
          "type": "DRUG"
        },
        {
          "name": "IK-175 and nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ikena Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2019-12-18",
      "completion_date": "2023-07-18",
      "has_results": false,
      "last_update_posted_date": "2024-03-15",
      "last_synced_at": "2026-10-19T20:27:23.621Z",
      "location_count": 10,
      "location_summary": "Gilbert, Arizona • Sarasota, Florida • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04200963"
    },
    {
      "nct_id": "NCT03430791",
      "title": "Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab 240 mg IV",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab 3 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab 1 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "NovoTTF200A (Optune)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Baptist Health South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2018-12-05",
      "completion_date": "2021-01-27",
      "has_results": true,
      "last_update_posted_date": "2023-02-02",
      "last_synced_at": "2026-10-19T20:27:23.621Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03430791"
    },
    {
      "nct_id": "NCT02628574",
      "title": "Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "TRX518 monotherapy",
          "type": "DRUG"
        },
        {
          "name": "TRX518 with gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "TRX518 with pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "TRX518 with nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Leap Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 109,
      "start_date": "2016-01",
      "completion_date": "2020-07-14",
      "has_results": false,
      "last_update_posted_date": "2025-08-03",
      "last_synced_at": "2026-10-19T20:27:23.621Z",
      "location_count": 6,
      "location_summary": "Chicago, Illinois • Albuquerque, New Mexico • Cleveland, Ohio + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02628574"
    }
  ]
}